

Supplementary Material

Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome

Sabine Seidel, Michelle Margold, Thomas Kowalski, Alexander Baraniskin, Roland Schroers, Agnieszka Korfel, Eckhard Thiel, Michael Weller, Peter Martus and Uwe Schlegel

Table S1. Chemotherapy protocol including rituxumab and temozolomide.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 14
<i>Cycle 1 (1 cycle = 28 days)</i>							
Rituximab 375 mg/m ² IV	x						x
Temozolomide 150 mg/m ² PO		x	x	x	x	x	
<i>Cycles 2–6^a (1 cycle = 28 days)</i>							
Rituximab 375 mg/m ² IV	x						x
Temozolomide 200 mg/m ² PO		x	x	x	x	x	

^a Follow-up MRI planned after three cycles. Abbreviations: IV, intravenous; PO, per os.

Table S2. Outcome according to subgroup (*n* = 34).

Reason for Exclusion	No. of Patients	Age Range (y)	Response after Treatment	OS (months)
KPS < 30 because of PCNSL	6	66–81	CR <i>n</i> = 3 PD <i>n</i> = 1 Treatment discontinuation <i>n</i> = 2	1 (median)
KPS < 50 ^b independent of diagnosis of PCNSL	1	60	PD	20
Psychiatric comorbidity	2	26/79	CR <i>n</i> = 2	14/2
Immunosuppression	7	52–75	CR/CRu <i>n</i> = 4 PD <i>n</i> = 2 TD <i>n</i> = 1	14 (median)
Previous malignancy	3	77–83	CR <i>n</i> = 2 PD <i>n</i> = 1	16 (median)
Heart insufficiency	3	66–74	CR <i>n</i> = 3	31

				(median)
Renal insufficiency	5	75–80	PR 1 PD 2 No treatment 2	2 (median)
KPS < 50 ^b and psychiatric comorbidity	3	69–79	CR <i>n</i> = 1 PD <i>n</i> = 1 TD <i>n</i> = 1	2 (median)
KPS < 30 and heart insufficiency	1	74	CR	68
KPS < 30 and psychiatric comorbidity	1	62	CR	14
Heart and renal insufficiency	1	75	PD	14
Immunosuppression and renal insufficiency	1	80	No treatment	2

Abbreviations: CR, complete remission; CRu, complete remission unconfirmed; KPS, Karnofsky performance score; OS, overall survival; PD, progressive disease, PR, partial remission; TD, toxic death.

Table S3. Treatment characteristics (*n* = 34).

	No. of Patients
<i>HDMTX application</i>	
Yes	27 (79.4%)
No	7 (20.6%)
<i>Rituximab application</i>	
Yes	23 (67.6%)
No	11 (32.4%)
<i>First-line treatment</i>	
HDMTX and AraC-based polychemotherapy	10 (29.4%)
HDMTX and AraC-based polychemotherapy + ICV	13 (38.2%)
HDMTX and AraC-based polychemotherapy + ITH liposomal AraC	3 (8.8%)
Rituximab + temozolomide	3 (8.8%)
WBRT	1 (2.9%)
HD-ASCT	1 (2.9%)
Palliative treatment	3 (8.8%)
<i>Second-line treatment (n = 12)</i>	
Temozolomide	4
Rituximab + temozolomide	2
MTX + rituximab + temozolomide	1
WBRT	2
HD-ASCT	2
R-CHOP (systemic relapse)	1
<i>Third-line treatment (n = 3)</i>	
HD-ASCT	1
R-CHOP (systemic relapse)	1
Temsirolimus	1

Abbreviations: AraC, cytarabine; HDMTX, high-dose methotrexate; ICV, intracerebroventricular; ITH, intrathecal; WBRT, whole-brain radiation therapy; HD ASCT, high-dose chemotherapy with autologous stem-cell transplantation.